



To: House Committee on Energy & Commerce
Oversight & Investigations subcommittee

April 10, 2019

The Endocrine Society appreciates Congressional attention to the issue of rising insulin prices and is happy to work with policymakers to identify meaningful solutions.

The expansion of Sanofi's ValYOU program is good news for people without insurance coverage for their insulin. While this is an important option for the uninsured patient, the price of insulin remains a major challenge for many patients on Medicare or with high deductible plans.

The Endocrine Society continues to urge drug manufacturers, insurance companies, and pharmacy benefit managers to work together to stop the spiraling cost of insulin and other medications that has led to an ever-growing patchwork of complex, confusing, and difficult to access safety net programs.

Contact:

Mila N. Becker, JD
Chief Policy Officer, Endocrine Society
202.971.3633
mbecker@endocrine.org

Meredith Dyer
Director, Health Policy, Endocrine Society
202.971.3637
mdyer@endocrine.org

2055 L Street NW
Suite 600
Washington, DC
20036

T. 202.971.3636
F. 202.736.9705

endocrine.org

Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our website at endocrine.org. Follow us on Twitter at [@TheEndoSociety](https://twitter.com/TheEndoSociety) and [@EndoMedia](https://twitter.com/EndoMedia).